IceCure Medical (NASDAQ:ICCM – Get Free Report) and TransMedics Group (NASDAQ:TMDX – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.
Insider and Institutional Ownership
0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by insiders. Comparatively, 6.9% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings for IceCure Medical and TransMedics Group, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IceCure Medical | 1 | 1 | 2 | 0 | 2.25 |
| TransMedics Group | 0 | 7 | 5 | 0 | 2.42 |
IceCure Medical currently has a consensus price target of $30.00, suggesting a potential upside of 3,694.59%. TransMedics Group has a consensus price target of $115.60, suggesting a potential upside of 58.90%. Given IceCure Medical’s higher probable upside, analysts clearly believe IceCure Medical is more favorable than TransMedics Group.
Profitability
This table compares IceCure Medical and TransMedics Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IceCure Medical | -427.67% | -174.26% | -112.58% |
| TransMedics Group | 22.69% | 15.88% | 5.95% |
Valuation & Earnings
This table compares IceCure Medical and TransMedics Group”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IceCure Medical | $3.38 million | 0.80 | -$15.06 million | ($8.52) | -0.09 |
| TransMedics Group | $605.49 million | 4.15 | $190.29 million | $3.89 | 18.70 |
TransMedics Group has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
IceCure Medical has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500.
Summary
TransMedics Group beats IceCure Medical on 12 of the 13 factors compared between the two stocks.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
About TransMedics Group
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
